Treace Medical Concepts (TMCI) Gross Margin (2020 - 2026)

Treace Medical Concepts (TMCI) has reported Gross Margin for 7 consecutive years, with 78.47% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Margin fell 120.0% year-over-year to 78.47%; the trailing twelve-month figure through Jun 2026 stood at 79.45% (down 67.0% YoY), and the FY2025 full-year result was 79.81%, down 56.0% from the prior year.
• Gross Margin fell to 78.47% in Q2 2026 per TMCI's latest filing, from 79.26% in the prior quarter.
• Across five years, Gross Margin topped out at 82.34% in Q2 2022 and bottomed at 78.47% in Q2 2026.
• Historically, Gross Margin has averaged 80.6% across 5 years, with a median of 80.5% in 2023.
• The widest YoY moves for Gross Margin: up 144 bps in 2022, down 207 bps in 2022.
• Over 5 years, Gross Margin stood at 81.87% in 2022, then decreased by 0 bps to 81.56% in 2023, then dropped by 1 bps to 80.74% in 2024, then retreated by 0 bps to 80.62% in 2025, then dropped by 3 bps to 78.47% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 78.47%, 79.26%, and 80.62% for Q2 2026, Q1 2026, and Q4 2025 respectively.